Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26F91XL
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $129,035
Award facts
- Contract value 100% obligated
- $129,035.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $129,035.16, awards Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) a firm fixed-price contract for REPATHA 140 mg/ml SureClick auto-injectors through the Defense Logistics Agency (DLA). The award, issued on January 14, 2026, with an ultimate completion date of January 15, 2026, represents a non-set-aside, competitively awarded transaction. The place of performance is Conshohocken, Pennsylvania, where Amerisourcebergen Drug Corp maintains its corporate headquarters. This delivery order is executed under Amerisourcebergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), a $999,999,999.00 vehicle through December 2026 that serves as the primary procurement mechanism for pharmaceutical and medical supply deliveries supporting military healthcare programs globally.
REPATHA (evolocumab) is a PCSK9 inhibitor injectable medication used to treat high cholesterol and reduce cardiovascular risk in eligible patient populations. The DLA procures this specialty pharmaceutical through its established pharmaceutical supply chain to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. Amerisourcebergen's role as a critical pharmaceutical distributor enables efficient fulfillment of federal medical supply requirements across multiple therapeutic domains, including specialty medications essential for chronic disease management within the military health system.
Quick answers
Who was awarded contract SPE2DR26F91XL?
SPE2DR26F91XL was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26F91XL worth?
The government has obligated $129,035 on SPE2DR26F91XL.
Is contract SPE2DR26F91XL an order under another contract?
Yes. SPE2DR26F91XL is a delivery order under SPE2DR25D2103, an indefinite delivery contract.
Was contract SPE2DR26F91XL competed?
The extent of competition for SPE2DR26F91XL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award